Abstract
We conducted a randomized, open-label, controlled trial to assess the efficacy of oxcarbazepine for prophylaxis against oxaliplatin-induced peripheral neuropathy (OxIN). Thirty-two patients with colon cancer received 12 courses of the FOLFOX-4 regimen and were randomly assigned to receive oxcarbazepine (600 mg BID) or chemotherapy without oxcarbazepine. The incidence of OxIN was strikingly decreased in patients receiving oxcarbazepine (31.2% vs 75%). Oxcarbazepine may prevent OxIN symptoms. Further larger placebo-controlled trials are warranted to confirm our results.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Anticonvulsants / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Colorectal Neoplasms / drug therapy
-
Drug Combinations
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neuroprotective Agents / administration & dosage
-
Organoplatinum Compounds / adverse effects*
-
Oxaliplatin
-
Peripheral Nervous System Diseases / chemically induced*
-
Peripheral Nervous System Diseases / prevention & control*
-
Treatment Outcome
Substances
-
Anticonvulsants
-
Antineoplastic Agents
-
Drug Combinations
-
Neuroprotective Agents
-
Organoplatinum Compounds
-
Oxaliplatin